Lexicon Pharmaceuticals (NASDAQ:LXRX) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a report issued on Monday morning,Benzinga reports. They currently have a $4.00 price objective on the biopharmaceutical company’s stock.

Separately, Needham & Company LLC reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Wednesday, January 29th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $5.00.

Lexicon Pharmaceuticals Stock Down 58.2 %

Shares of LXRX opened at $0.29 on Monday. Lexicon Pharmaceuticals has a 12-month low of $0.28 and a 12-month high of $2.83. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $72.05 million, a PE ratio of -0.39 and a beta of 1.04. The business’s 50 day moving average is $0.76 and its 200 day moving average is $1.17.

Institutional Trading of Lexicon Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. Intech Investment Management LLC acquired a new position in shares of Lexicon Pharmaceuticals in the 3rd quarter worth approximately $115,000. Charles Schwab Investment Management Inc. grew its position in shares of Lexicon Pharmaceuticals by 4.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,417,295 shares of the biopharmaceutical company’s stock valued at $2,225,000 after buying an additional 58,147 shares during the last quarter. FMR LLC lifted its holdings in shares of Lexicon Pharmaceuticals by 28.9% in the 3rd quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company’s stock valued at $78,291,000 after purchasing an additional 11,179,919 shares during the last quarter. BNP Paribas Financial Markets raised its position in Lexicon Pharmaceuticals by 71.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 13,246 shares during the last quarter. Finally, BBR Partners LLC grew its holdings in shares of Lexicon Pharmaceuticals by 74.1% during the third quarter. BBR Partners LLC now owns 470,000 shares of the biopharmaceutical company’s stock worth $738,000 after buying an additional 200,000 shares during the last quarter. 74.70% of the stock is owned by institutional investors and hedge funds.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.